Background-Assessment of the quality of care for outpatients with heart failure (HF) has focused on the development and use of process-based performance measures, with the supposition that these care process measures are associated with clinical outcomes. However, this association has not been evaluated for current and emerging outpatient HF measures. Methods and Results-Performance on 7 HF process measures (4 current and 3 emerging) and 2 summary measures was assessed at baseline in patients from 167 US outpatient cardiology practices with patients prospectively followed up for 24 months. Participants included 15 177 patients with reduced left ventricular ejection fraction (Յ35%) and chronic HF or post-myocardial infarction. Multivariable analyses were performed to assess the process-outcome relationship for each measure in eligible patients. Vital status was available for 11 621 patients. The mortality rate at 24 months was 22.1%. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, ␤-blocker use, anticoagulant therapy for atrial fibrillation, cardiac resynchronization therapy, implantable cardioverter-defibrillators, and HF education for eligible patients were each independently associated with improved 24-month survival, whereas aldosterone antagonist use was not. The all-or-none and composite care summary measures were also independently associated with improved survival. Each 10% improvement in composite care was associated with a 13% lower odds of 24-month mortality (adjusted odds ratio, 0.87; 95% confidence interval, 0.84 to 0.90; PϽ0.0001).
with postdischarge clinical outcomes. 8 -12 These studies have informed efforts to update and revise inpatient HF performance measures. However, to date, similar studies have not been conducted to assess relationships between current or emerging outpatient process-of-care measures for HF and clinical outcomes. We used data from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) to examine the relationships between adherence to several current and emerging outpatient HF process measures and clinical outcomes.
Methods
The study population was the longitudinal cohort enrolled in IMPROVE HF, which contains data on demographics, clinical characteristics, processes of care, and certain outcomes for outpatients with HF. 13, 14 The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting was a prospective study designed to evaluate the effectiveness of a practice-specific performance improvement intervention on the use of selected evidence-based therapies for patients with diagnosed HF and reduced left ventricular ejection fraction or prior myocardial infarction and reduced left ventricular ejection fraction in outpatient cardiology practices. The methods and overall study objectives have been described previously. 13, 14 Practices invited to participate in IMPROVE HF included community and academic cardiology or multispecialty outpatient practices geographically dispersed throughout the United States. 13, 14 Eligibility criteria for patient enrollment in the IMPROVE HF cohort included a clinical diagnosis of HF or post-myocardial infarction and reduced left ventricular ejection fraction. Left ventricular systolic dysfunction was determined quantitatively by a left ventricular ejection fraction Յ35% or qualitatively based on findings of moderate to severe left ventricular systolic dysfunction on the most recent assessments by echocardiogram, nuclear multiple gated acquisition scan, contrast ventriculogram, or magnetic resonance imaging scan. 13, 14 Patients were excluded from enrollment in the IMPROVE HF cohort if they had a noncardiovascular medical condition associated with an estimated survival of Յ1 year or had received a cardiac transplantation.
Medical chart reviews were completed at baseline for all eligible patients from all participating practices to determine use rates for HF therapies. A practice-specific performance improvement initiative intervention was conducted after completion of baseline data collection, and adherence to care measures was reevaluated at prespecified time points during implementation of the intervention, which was conducted over a 24-month interval. Follow-up data on enrolled patients were collected by chart review. Data recorded for patients at baseline and each follow-up assessment included demographic and clinical characteristics, New York Heart Association (NYHA) functional status, QRS duration, laboratory results, diagnostic tests, treatments, and the provision of patient education about HF. In addition, documented contraindications or other reasons for not administering evidence-based therapies to eligible patients were recorded during each medical chart review. Other reasons for not providing evidence-based care to eligible patients included patient refusal or medical, economic, social, and religious reasons.
A representative sample of medical records from patients who met the study eligibility criteria were screened and selected at random to yield an average of 90 eligible patients for each practice enrolled in IMPROVE HF. As described in previous publications, rigorous measures were developed and followed to ensure data quality and accuracy. 13, 14 These included the use of 34 trained, centralized chart reviewers who received ongoing training and testing to maintain the accuracy of data abstraction. Members of the IMPROVE HF Steering Committee provided oversight for training of the medical chart reviewers and data abstraction process. 13 This resulted in an average interrater reliability between chart reviewers of 0.82 ( statistic). Monthly data quality reports and inclusion of an average of 1.7 automated data quality checks for each data field were also implemented to ensure that values met prespecified ranges, formats, and units. Additional data quality and verification efforts included audits of all patient data compared with source documentation, which was conducted for 20% of the entire patient sample and a 10% random sample of participating practices. 14 The mean data concordance rate was 94.5% (range, 92.3% to 96.3%). Institutional review board approval or waivers to participate in IMPROVE HF were required of all practices that took part in IMPROVE HF. The registry coordinating center was Outcome Sciences, Inc. (Cambridge, MA).
HF Outpatient Process Measures
Seven process-of-care-based quality measures were analyzed: (1) angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) use, (2) ␤-blocker use, (3) aldosterone antagonist use, (4) anticoagulant therapy for atrial fibrillation or flutter, (5) cardiac resynchronization therapy (CRT; with defibrillator or pacemaker), (6) implantable cardioverter-defibrillator (ICD; ICD or CRT with defibrillator), and (7) HF education for eligible patients. 13, 14 Four of these quality measures (ACEI or ARB, ␤-blocker, HF education, and anticoagulation for atrial fibrillation or flutter) are American College of Cardiology/American Heart Association (ACC/AHA) outpatient HF performance measures and are endorsed by the National Quality Forum; the 3 emerging measures (use of aldosterone antagonist, ICD, and CRT) are not ( Table I in the online-only Data Supplement). 6 Patients eligible for inclusion in calculations associated with each individual quality measure included only those who met the criteria for each specific therapy and for whom there were no contraindications, intolerance, or other documented reasons to explain why the indicated therapy was not provided. The detailed quality measure specifications have previously been published, and the 4 outpatient care measures endorsed by the ACC/AHA followed published specifications. 6, 13, 14 HF education was based on medical record documentation that written and/or verbal HF education was provided to patients. Documentation of NYHA functional class was required to be considered eligible for an ICD, CRT, or aldosterone antagonist, and analyses of these quality measures included only patients with quantitative or qualitative documentation of NYHA functional class at a level consistent with the measure specifications. 13, 14 Two summary (composite) measures were also calculated. The first was a total composite score, defined as the percentage of the total indicated quality measures provided. The second was an all-or-none care measure, defined as the proportion of patients who received each quality measure for which they were clinically eligible. 13, 14 Longitudinal Follow-Up Reviews of the medical records of patients eligible for enrollment in the longitudinal cohort were conducted at baseline and subsequently at 12 and 24 months after implementation of the performance improvement intervention. Medical records provided data on temporal changes in patient-specific quality measures and assessment of patient vital status. Practices were encouraged to contact patients who did not have follow-up visits and had received instructions on how to determine vital status using the National Death Index. Deaths reported through these mechanisms, if they occurred before the 24-month follow-up, were included in the mortality analyses. A total of 167 practices completed the baseline assessment, and 155 practices completed the 12-and 24-month follow-up assessments. An analysis of relationships between measure conformity and mortality was prespecified in the study protocol and statistical analysis plan.
Statistical Methods
Descriptive statistics for baseline patient and practice characteristics were calculated and reported. We used 2 tests and t tests to evaluate statistical associations for categorical and continuous data, respectively. Each quality measure was evaluated separately. For each quality measure, the proportion of patients receiving therapy at baseline among those eligible for that therapy at baseline was calculated for patients alive and deceased at the end of the 24-month follow-up interval. The composite score and all-or-none care measure were also calculated for patients with and without fatal events. The composite score for each patient was calculated as the sum of individual quality measure numerators divided by the sum of individual quality measure denominators for which the patient was eligible. The all-or-none care measure was defined for each patient in terms of whether they received all individual measures for which they were eligible. The outcome measure was mortality in the first 24 months after baseline entry into the study. The primary analysis examined associations between patient-level process measures and patient-level outcomes. Patients who were eligible for treatment but not treated at baseline and who crossed over within the first 12 months of the performance initiative were excluded from each measure. Generalized estimating equation (GEE) methodology was used to estimate unadjusted and adjusted relationships between each process measure and patient-level mortality in the first 24 months. The GEE models accounted for the correlation of patients within practices. The covariates in the analyses included the baseline patient demographic and clinical characteristics and practice characteristics, because they may be associated with process measure conformity and mortality. The initial models included the practice and patient characteristics shown in Tables 1 and 2 as possible predictors in the model if PϽ0.10 in the univariate analyses. The final multivariate GEE models included all covariates with PϽ0.20. Generalized estimating equation models were also developed for analyses of the all-or-none and composite score measures after adjustment for patient clinical characteristics and practice characteristics, taking into account the correlation of data within practices. To account for missing follow-up data, a sensitivity analysis was performed in which patients lost to follow-up were treated as alive at follow-up. Additional sensitivity analyses in which early crossover patients were not excluded and in which early crossover patients were counted as conforming to the process measures were also performed. We performed a sensitivity analysis confined to only those patients with NYHA class quantified. Finally, we analyzed the summary measures with only the 4 current process measures included. All statistical inference testing was 2 sided, with results considered statistically significant at PϽ0.05. Because this study was exploratory in nature, formal adjustments for multiple comparisons were not performed. Analyses were completed with SAS statistical software, version 9.1 (SAS Institute, Cary, NC).
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Results

Baseline Patient Characteristics
There were 15 177 patients from 167 outpatient cardiology practices in the United States who were evaluated at baseline and included in the longitudinal cohort. A median of 90 (25th to 75th percentile, 58 to 107) patients per practice were entered. At the 24-month follow-up, 11 621 of the 15 177 patients (76.6%) had documentation of vital status. A total of 2508 patients (16.5%) were lost to follow-up, and 1048 (6.9%) were seen in practices (nϭ12) that did not complete a 12-or 24-month follow-up assessment.
Baseline patient characteristics for the total cohort of patients enrolled in IMPROVE HF, those with vital status at 24 months, and those lost to follow-up are shown in Table 1 . The median age of patients in the total cohort was 70 years, and 71.1% were men. An ischemic origin for HF was identified in 65.4% of patients. A history of hypertension (62.2%), diabetes mellitus (34.1%), and atrial fibrillation (30.7%) was frequently identified. The median left ventricular ejection fraction was 25%. NYHA functional class was quantitatively documented in 34.2% and qualitatively documented by symptoms and functional limitations in an additional 60.3% of medical records (94.5% total). The characteristics of patients with and without complete vital status data were similar (Table 1 ).
Practice Characteristics
All geographic regions of the country were represented in IMPROVE HF. Most participating practices were not associated with a university center; 41.3% reported having a dedicated HF clinic, and only 9.6% were associated with a heart transplantation program. Of the participating practices, 24.1% were multispecialty. The characteristics of practices participating in IMPROVE HF at the patient level are shown in Table 2 . The practice characteristics for those patients with and without complete vital status were similar ( Table 2 ).
Process-of-Care Measures
The conformity with the 7 process-of-care HF measures and 2 summary measures at baseline in eligible patients with documentation of vital status at 24 months is shown in Table  3 . Rates of baseline conformity ranged from 34.9% for the aldosterone antagonist measure to 86.5% for the ␤-blocker measure. At baseline, 2815 of 11 621 patients (24.2%) conformed to the all-or-none care measure, and the composite score measure was 68.6% (Table 3) .
Process Measure Outcome Association
At 24 months, 2569 of the 11 621 patients (22.1%) with complete vital status had died. The baseline demographics and characteristics of patients alive at the 24-month assessment and those who had died are shown in Table II in the online-only Data Supplement. Patients who died were significantly more likely to have ischemic HF origin and comorbidities, including diabetes mellitus, hypertension, chronic obstructive pulmonary disease, peripheral vascular disease, and depression. Statistically significant differences were also evident for laboratory evaluations, including blood urea nitrogen and creatinine, with higher levels in patients who had died during the 24-month follow-up period. The baseline process measure conformity was significantly lower among patients who died compared with those who survived for 5 of the 7 individual measures ( Table 3 ). There were no differences in aldosterone antagonist use or HF education measures among survivors and nonsurvivors. Both the composite score and all-or-none measure conformity rates were significantly higher among survivors than among those patients who did not survive 24 months (Table 3) .
As shown in Table 4 , the unadjusted mortality rates were numerically higher for patients without conformity to the process measures at baseline compared with those whose care conformed for 6 of the 7 individual process measures and the all-or-none measure. The baseline process measure composite score was 70.0% for patients alive at 24 months compared with 63.4% of those who were deceased (PϽ0.0001; Table 3 ).
Fonarow et al Heart Failure Care Processes and Outcome
Univariate GEE analysis revealed that 6 of the 7 process measures were associated with improved survival, with odds ratios ranging from 0.40 to 0.68. After adjustment for multiple patient and practice covariates ( Table III in the online-only Data Supplement), 6 of 7 process measures were significantly associated with lower mortality risk on multivariable GEE analysis (Table 4 ). Aldosterone antagonist use was the only process measure that was not associated with NYHA indicates New York Heart Association. Variables that were not completely documented in medical records in the longitudinal cohort are as follows: heart failure origin, 914 (6.0%); left ventricular ejection fraction, 283 (1.9%); systolic blood pressure, 276 (1.8%); diastolic blood pressure, 299 (2.0%); heart rate, 993 (6.5%); pulmonary rales, 3159 (20.8%); edema, 4559 (30%); sodium, 2168 (14.3%); blood urea nitrogen, 2117 (13.9%); creatinine, 2040 (13.4%); potassium, 2058 (13.6%); and QRS duration, 4952 (32.6%). decreased mortality risk; after GEE multivariate adjustment, there was a statistically nonsignificant increased odds of mortality. In multivariable GEE analyses, the all-or-none summary measure was associated with significantly lower risk-adjusted mortality at 24 months. The adjusted odds for mortality risk for patients with conformity to each measure for which they were eligible was 38% lower than for those whose care did not conform for Ն1 measures for which they were eligible (adjusted odds ratio, 0.62; 95% confidence interval, 0.52 to 0.75; PϽ0.0001; Table 4 ). Every 10% improvement in composite care was associated with a 13% lower odds of 24-month mortality risk (adjusted odds ratio, 0.87; 95% confidence interval, 0.84 to 0.90; PϽ0.0001). Sensitivity analyses were performed, in which patients without process measure conformity at baseline, but with crossover to measure conformity within the first 12 months after baseline, were not excluded, but counted as untreated. These analyses produced similar findings except, after multivariable adjustment in the GEE model, HF education was no longer associated with reduced mortality risk, the P value for the CRT measure was not significant (Pϭ0.06), and aldosterone antagonist use was associated with increased risk ( Table  IV in the online-only Data Supplement). Additional sensitivity analyses revealed that classification of patients with missing data as alive at follow-up yielded similar findings, except the P value for the CRT measure was 0.056 and the anticoagulation for atrial fibrillation or flutter measure was not significant ( Table V in the online-only Data Supplement). Similar results were also obtained with an approach in which early crossover patients were not excluded from the model but were counted as conforming (Table VI in the online-only Data Supplement). When the analyses for the aldosterone antagonist, ICD, and CRT measures were confined to only those patients in whom NYHA class was quantified, the findings were similar, but with stronger associations for CRT and ICD measures with reduced mortality (Table VII in the online-only Data Supplement). When the summary measures were analyzed using only the 4 ACC/AHA-endorsed process measures (ACEI/ARB, ␤-blocker, anticoagulation for atrial fibrillation, and HF education), there were significant associations with survival, although the odds ratio was less robust for the more limited all-or-none summary measure compared with the all-or-none measure when all 7 process measures were included (Table 4 and Table VIII in the online-only Data Supplement).
Discussion
This study is among the first to examine whether, and the degree to which, conformity with current and emerging HF process-based quality measures is associated with clinical outcomes in a contemporary cohort of outpatients with HF. Analysis of IMPROVE HF data revealed that all 4 current ACC/AHA HF outpatient performance measures were associated with decreased risk of 24-month mortality. In addition, the emerging process measures of ICD therapy and CRT for eligible patients were significantly associated with lower adjusted risk of mortality. For the 2 summary measures of HF care processes, there was also a strong positive association between greater conformity to the summary measures and improved risk-adjusted survival. These findings may have significant clinical and public health implications, providing evidence to suggest that current, and some emerging, outpatient process measures may effectively reflect the quality of care provided to patients with HF who are treated in outpatient practice settings.
It is implicit in the stated goals for the development, selection, and implementation of process-based performance measures that there should be a process-outcome association for each measure. 6, 7, 9 Performance measures for acute myocardial infarction have been well validated, with good process-outcome associations for most measures in most published studies. [15] [16] [17] In contrast, some of the HF performance measures for the hospital setting were not associated with improved clinical outcomes. 8 -12 Findings from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) revealed that none of the 4 Center for Medicare and Medicaid Services/The Joint Commission process measures for HF in the inpatient setting were associated with patient-level or hospital-level postdischarge mortality, and that only the measure for ACEI or ARB in patients with left ventricular systolic dysfunction was associated with postdischarge mortality or readmission. 9,10 A nationwide study of the HF discharge counseling measure also found no relationship with CI indicates confidence interval; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AF, atrial fibrillation; ICD, implantable cardioverter-defibrillator; CRT-D, cardiac revascularization therapy with defibrillator; CRT-P, CRT with pacemaker; and HF, heart failure.
*Odds ratio and confidence interval for composite care score are based on a 10-unit increase in composite. Patients who crossed over to treatment during the first 12 months were excluded from analysis. For the composite care measure, individual process measures with early crossover to treatment were excluded.
30-day rehospitalization rates. 12 The extent to which conformity with current or emerging HF process-based measures can affect quality of care and outcomes in contemporary outpatients with HF has not been well studied. Limited sets of process measures are being implemented in performance improvement programs and are beginning to be used to publicly report the quality of HF care delivery in outpatient practices and for individual physicians. In addition, Medicare and other payers are evaluating pay-for-performance incentive programs, so performance on process measures soon may also affect financial compensation to practices and individual physicians. 7 Therefore, it is essential that measures be prioritized to include those that are proven to be valid and closely associated with relevant clinical outcomes. 7, 9, 11 The findings of strong associations between ACEI or ARB use and ␤-blocker use in eligible HF outpatients and improved survival are consistent with the wealth of clinical trial data demonstrating the efficacy of these therapies 2 and with prior studies showing that ACEI/ARB and ␤-blocker process measures at the time of hospital discharge are associated with improved outcomes. 9 -11,18 A study of Medicare patients showed that a discharge prescription for either an ACEI or ARB was associated with a 17% relative reduction in 1-year postdischarge mortality after risk adjustment. 18 A study of Medicare beneficiaries hospitalized with HF and enrolled in OPTIMIZE-HF found that the process measure of use of ␤-blocker therapy at hospital discharge was independently associated with improved survival. 11 The current IMPROVE HF study provides further evidence supporting the processoutcome association for ACEI/ARB and ␤-blocker use and extends these findings to outpatients and a cohort not entirely limited to Medicare patients.
The finding of improved outcomes with the HF education outpatient process measure may seem to conflict with prior studies demonstrating that the Center for Medicare and Medicaid Services/The Joint Commission process measure for hospital discharge instructions is not associated with improved postdischarge outcomes. 9,10,12 However, it is unclear whether the hospital discharge instruction process measure that is abstracted from hospital medical records truly reflects whether patients received each defined component of education. Patient education may be documented in the hospital medical record, although it may have been provided in a rushed or superficial manner at discharge. This would make it less likely that patients would retain the information. 19 In contrast, documentation of HF education in the outpatient cardiology practice setting may be more representative of physicians or nurses providing patients with detailed instructions on medications, diet, symptoms of worsening HF, and daily weight monitoring. This measure might more effectively distinguish the quality of care and outcomes for outpatients with HF. In the present analysis, the anticoagulation for atrial fibrillation process measure was also associated with a reduced risk of mortality. This finding is consistent with clinical trials demonstrating that anticoagulation for atrial fibrillation reduces the risk of fatal and nonfatal stroke in patients with HF. 2, 20 This study also provides evidence to support potential expansion of HF outpatient process measures to include additional measures associated with clinical outcomes. Use of CRT and ICD therapies has been shown to reduce mortality in randomized clinical trials, and these therapies are Class I recommendations for eligible patients in the ACC/AHA HF guidelines. 2 After adjustment for covariates, conformity with the ICD process measure in eligible patients was significantly associated with a 38% lower odds of 2-year mortality. Prior studies have also shown that ICD use in eligible patients at the time of hospital discharge is associated with reduced mortality over 1-and 3-year periods. 11, 21 The processoutcome association of the ICD measure provides a potential rationale for incorporation into standard performance measures of quality of care for HF. The writing group for the 2010 draft of ACC/AHA HF performance measures has proposed ICD counseling in eligible patients as an outpatient HF performance measure. In this study, the CRT process measure rate was higher in patients alive at 24 months, and this measure was also significantly associated with lower odds of mortality in some, but not all, of the multivariable analyses. CRT has previously been shown to be clinically effective in patients with HF. 22 A CRT use process measure could also be considered to quantify the quality of outpatient HF care, but further study is required.
In contrast, the aldosterone antagonist process measure was not associated with lower mortality, and after multivariable adjustment was actually associated with a nonsignificant trend for higher mortality risk. These findings are in contrast to randomized clinical trials demonstrating efficacy 2 and a prior study of an aldosterone antagonist use at hospital discharge process measure that reported lower mortality risk with use of aldosterone antagonists. 11 Further studies are needed, but these findings suggest that concerns regarding an aldosterone antagonist process measure may be justified. 23 Our results suggest that, with a single exception, the outpatient HF process measures selected for IMPROVE HF may reflect the quality of care provided, and could potentially serve as a vehicle for more rapid translation of the strongest clinical evidence into practice. Given the independent associations between these individual process measures and both summary measures and patient survival, the use of these process measures in HF performance improvement programs may be an effective way to measure and improve the quality of HF care. Because this study evaluated process measures at the patient level, it is important for additional studies to evaluate current and emerging process measures at the practice level. These practice-level studies may produce different results. Results of this study may also suggest that successful efforts to improve conformity with these outpatient HF process measures, with the possible exception of aldosterone antagonists, would be expected to translate into a favorable impact on clinical outcomes. 14 However, only those HF process measures that have been selected by the ACC/AHA Task Force on Performance Measures should be considered performance measures and used for accountability. 24 In addition to process measures, direct reporting of clinical outcomes such as symptom control, health status, risk-adjusted hospitalization rates, and risk-adjusted mortality are also important.
Fonarow et al Heart Failure Care Processes and Outcome Limitations
This study included a diverse group of patients with HF from a wide variety of university and nonuniversity outpatient cardiology practices. The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting also contains far more detailed information on patient characteristics, presenting symptoms, diagnostic studies, treatments, and outcomes than has been available in prior administrative data sets or registries in the outpatient setting. However, certain limitations are inherent in the design of IMPROVE HF, and interpretation of the results from these analyses should acknowledge these limitations. Medical chart review with data abstraction was the source of patient clinical data. Every effort was made to ensure the accuracy and completeness of these data through consistent, regular training of personnel involved in the medical chart review process, but it is possible that errors and omissions could have occurred. Of note, determination of patient eligibility and treatment rates for each of the 7 process measures was based on documentation in the medical records. Thus, there is the potential that variations in the data abstraction process between chart reviewers or inaccuracies or omissions in the medical record could account for some of the differences in outcomes found in this study. It is also possible that some proportion of patients considered eligible for treatment who were not treated may have had contraindications or other reasons that prevented treatment, but were not documented in the medical record. New York Heart Association functional status was not quantified in many of the records, and was instead based on qualitative description of the patients' functional status. It is important to note that this study analyzed medications prescribed rather than actual patient adherence to the medical regimen prescribed. Follow-up on vital status was not achieved for all patients. Although the amount of missing data is greater than that reported for clinical trials, the level of missing data seen in IMPROVE HF may be within expectations given the variances in patient mobility and access to care in outpatient clinical practice settings. However, the missing vital status in a portion of patients may reduce the external validity of these findings. The associations between care processes and outcomes do not determine causality. Although these associations may reflect the quality of clinical care, they may alternatively reflect treatment selection bias, which would tend to favor these associations. The process measure-outcome association can be confounded by patient age, sex, race/ethnicity, comorbid conditions, disease severity, health insurance, socioeconomic factors, and patient adherence to prescribed therapies. The multivariable models used in this study adjusted for age, sex, multiple comorbidities, and health insurance status, but it was not possible to adequately adjust for race/ethnicity owing to the number of patients for which race/ethnicity was not documented. Furthermore, we could not adjust for socioeconomic factors or patient adherence. There may also be other measured or unmeasured confounding variables that would have strengthened or weakened the process-outcome association for some or all of the process measures. The odds ratios may have been magnified by confounding, particularly for the ICD and CRT process measures. The use of summary measures may minimize distinctions between individual process measures. We did not assess health-related quality of life, symptom control, functional capacity, patient satisfaction, hospitalization rates, or other clinical outcomes that may be of interest, and the HF process measures may or may not be associated with these outcomes. Patients in IMPROVE HF were selected from a representative sample from each practice, had documented left ventricular function, and had at least 2 office visits with a cardiologist in the last 2 years. These factors may have introduced some ascertainment bias, so these patients may not be entirely representative of the population of patients with HF in outpatient cardiology practices. Outpatient cardiology practices self-selected to participate in IMPROVE HF. Thus, these findings may not apply to practices that differ from the IMPROVE HF outpatient cardiology practices with regard to variables such as patient case mix, baseline care patterns, motivation, and resources. We also do not know how well these HF process measures would perform in primary care or other outpatient settings.
Conclusions
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